696 related articles for article (PubMed ID: 30427749)
21. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
[TBL] [Abstract][Full Text] [Related]
22. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP
Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211
[TBL] [Abstract][Full Text] [Related]
26. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.
Eriksson M; Käyhty H; Saha H; Lahdenkari M; Koskinen P; Mäkisalo H; Anttila VJ
Transpl Infect Dis; 2020 Aug; 22(4):e13343. PubMed ID: 32473046
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
[TBL] [Abstract][Full Text] [Related]
29. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
Wilck M; Cornely OA; Cordonnier C; Velez JD; Ljungman P; Maertens J; Selleslag D; Mullane KM; Nabhan S; Chen Q; Dagan R; Richmond P; Daus C; Geddie K; Tamms G; Sterling T; Patel SM; Shekar T; Musey L; Buchwald UK;
Clin Infect Dis; 2023 Oct; 77(8):1102-1110. PubMed ID: 37338158
[TBL] [Abstract][Full Text] [Related]
30. A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.
Meyer J; Silas P; Ouedraogo GL; McElwee K; Keep G; Trammel J; Peng Y; Scully IL; Gruber WC; Scott DA; Watson W
Pediatr Infect Dis J; 2024 Jun; 43(6):574-581. PubMed ID: 38502894
[TBL] [Abstract][Full Text] [Related]
31. Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
Ciprero KL; Marchese RD; Richard P; Baudin M; Sterling TM; Manoff SB; Radley D; Stek JE; Soubeyrand B; Grabenstein JD; Samson SI; Musey LK
Hum Vaccin Immunother; 2016 Aug; 12(8):2135-2141. PubMed ID: 27002793
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China.
Zhu F; Hu Y; Li J; Ye Q; Young MM; Liang JZ; Gruber WC; Giardina PC; Scott DA
Pediatr Infect Dis J; 2019 Nov; 38(11):1150-1158. PubMed ID: 31626050
[TBL] [Abstract][Full Text] [Related]
33. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
Kanevsky I; Surendran N; McElwee K; Lei L; Watson W; Pride M; Scully I; Karauzum H; Anderson A; Young M
Vaccine; 2023 Oct; 41(45):6625-6629. PubMed ID: 37793976
[TBL] [Abstract][Full Text] [Related]
34. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; El Sahly HM; George S; Winokur P; Edwards K; Brady RC; Rouphael N; Keitel WA; Mulligan MJ; Burton RL; Nakamura A; Ferreria J; Nahm MH
Vaccine; 2018 Jan; 36(5):606-614. PubMed ID: 29279281
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
Quinn CT; Wiedmann RT; Jarovsky D; Lopez-Medina E; Rodriguez HM; Papa M; Boggio G; Shou Q; Dagan R; Richmond P; Feemster K; McFetridge R; Tamms G; Lupinacci R; Musey L; Bickham K
Blood Adv; 2023 Feb; 7(3):414-421. PubMed ID: 36383730
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.
Xie J; Zhang Y; Caro-Aguilar I; Indrawati L; Smith WJ; Giovarelli C; Winters MA; MacNair J; He J; Abeygunawardana C; Musey L; Kosinski M; Skinner JM
Pediatr Infect Dis J; 2020 Jan; 39(1):70-77. PubMed ID: 31725555
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
[TBL] [Abstract][Full Text] [Related]
38. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
[No Abstract] [Full Text] [Related]
39. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial.
Idoko OT; Mboizi RB; Okoye M; Laudat F; Ceesay B; Liang JZ; Le Dren-Narayanin N; Jansen KU; Gurtman A; Center KJ; Scott DA; Kampmann B; Roca A
Vaccine; 2017 May; 35(24):3256-3263. PubMed ID: 28479175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
